These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 28823713

  • 1. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [Abstract] [Full Text] [Related]

  • 2. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology.
    Vietti Violi N, Gnerre J, Law A, Hectors S, Bane O, Doucette J, Abboud G, Kim E, Schwartz M, Fiel MI, Taouli B.
    Eur Radiol; 2022 Sep; 32(9):6493-6503. PubMed ID: 35380226
    [Abstract] [Full Text] [Related]

  • 3. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V.
    Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
    [Abstract] [Full Text] [Related]

  • 4. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R.
    Hepatology; 2013 Nov; 58(5):1655-66. PubMed ID: 23703789
    [Abstract] [Full Text] [Related]

  • 5. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.
    Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF.
    Radiology; 2014 Dec; 273(3):746-58. PubMed ID: 25028783
    [Abstract] [Full Text] [Related]

  • 6. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [Abstract] [Full Text] [Related]

  • 7. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G.
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [Abstract] [Full Text] [Related]

  • 8. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
    Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B.
    AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
    [Abstract] [Full Text] [Related]

  • 9. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
    El-Gazzaz G, Sourianarayanane A, Menon KV, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F.
    Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
    [Abstract] [Full Text] [Related]

  • 10. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.
    Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim MJ.
    Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360
    [Abstract] [Full Text] [Related]

  • 11. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M.
    World J Gastroenterol; 2017 May 28; 23(20):3690-3701. PubMed ID: 28611522
    [Abstract] [Full Text] [Related]

  • 12. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.
    Kim S, Mannelli L, Hajdu CH, Babb JS, Clark TW, Hecht EM, Taouli B.
    J Magn Reson Imaging; 2010 Feb 28; 31(2):348-55. PubMed ID: 20099348
    [Abstract] [Full Text] [Related]

  • 13. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.
    Donati OF, Do RK, Hötker AM, Katz SS, Zheng J, Moskowitz CS, Beattie C, Brown KT.
    Eur Radiol; 2015 Sep 28; 25(9):2779-88. PubMed ID: 25850892
    [Abstract] [Full Text] [Related]

  • 14. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
    Ahmed AF, Samreen N, Grajo JR, Zendejas I, Sistrom CL, Collinsworth A, Esnakula A, Shah JL, Cabrera R, Geller BS, Toskich BB.
    Abdom Radiol (NY); 2018 Jul 28; 43(7):1825-1836. PubMed ID: 29052747
    [Abstract] [Full Text] [Related]

  • 15. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF.
    Cardiovasc Intervent Radiol; 2018 Mar 28; 41(3):433-442. PubMed ID: 29086058
    [Abstract] [Full Text] [Related]

  • 16. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A, Huynh TJ, Rajan DK, Marquez MA, Grant DR, Huynh DC, Jaskolka JD.
    J Vasc Interv Radiol; 2013 Jun 28; 24(6):805-12. PubMed ID: 23562641
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N, Kim MS, Park MS, Choi JY, Do RKG, Han K, Kim MJ.
    Eur Radiol; 2020 Jan 28; 30(1):261-271. PubMed ID: 31418085
    [Abstract] [Full Text] [Related]

  • 18. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS.
    Ann Oncol; 2013 Apr 28; 24(4):965-73. PubMed ID: 23223331
    [Abstract] [Full Text] [Related]

  • 19. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
    Labeur TA, Runge JH, Klompenhouwer EG, Klümpen HJ, Takkenberg RB, van Delden OM.
    Abdom Radiol (NY); 2019 Aug 28; 44(8):2740-2750. PubMed ID: 31069479
    [Abstract] [Full Text] [Related]

  • 20. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
    Vouche M, Salem R, Lewandowski RJ, Miller FH.
    Abdom Imaging; 2015 Aug 28; 40(6):1471-80. PubMed ID: 25412868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.